Physicians' Academy for Cardiovascular Education
PCSK9 inhibition is associated with regression of tendon xanthomas in FH

PCSK9 inhibition is associated with regression of tendon xanthomas in FH

Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia

Literature - Bea AM, Perez-Calahorra S, Marco-Benedi V, et al. - Atherosclerosis 2017 Jun 8;263:92-96.

Main results

Conclusion

In a prospective case-control study with HeFH patients treated with potent statins, addition of a PCSK9 antibody resulted in a greater decrease in LDL-c and TX thickness after on average 3 years of treatment.

References

Show references

Find this article online at Atherosclerosis

Share this page with your colleagues and friends: